Addressing Real World Challenges
in Osteoporosis

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

June 1, 2009

Expiration Date:

June 1, 2011

Intended Audience:

This symposium has been conceived for the following audience:

• Internal medicine specialists
• Primary care special ists
• Family medicine specialists
• Endocrinologists
• Bone metabolism experts
• Women’s health physi cians
• Preventive medicine specialists
• Geriatricians
• Gynecologists
• Osteopathic physicians
• Nurse practitioners
• Geriatric nurse practitioners
• Rheuma tologists
• Consulting pharmacists

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Novartis Pharmaceuticals.
 

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Mone Zaidi, MD, PhD, FRCP
Professor of Medicine and Physiology
Director, The Mount Sinai Bone Program
Mount Sinai School of Medicine
New York, NY

Speaker’s Bureau: Procter &Gamble, Sanofi Aventis, Roche, GSK, Novartis

Felicia Cosman, MD – Program Moderator – Case Study Section
Clinical Director, National Osteoporosis Foundation
Medical Director of the Clinical Research Center
Helen Hayes Hospital
West Haverstraw, New York
Professor of Clinical Medicine
Columbia University
New York, NY

Grant/Research Support: Eli Lilly
Consultant: Eli Lilly, Merck, Novartis, Pfizer, Roche
Speaker’s Bureau: Eli Lilly, Merck, Roche

Anthony I. Sebba, MD, FACR
Assistant Clinical Professor
Department of Rheumatology
University of South Florida
Tampa, FL

Grant/Research: Roche
Consultant: Roche, Novartis
Speaker’s Bureau: Roche, GSK, Novartis, Lilly

Richard S. Haber, MD
Professor of Medicine, Endocrinology, Diabetes and Bone Disease
Director, Bone Densitometry Program
Mount Sinai School of Medicine
New York, NY

No information to disclose

Educational Objectives:

Participants in this CME-certified WebCAST will:

• Learn to stratify patients at risk for osteoporosis and/or related complications and identify optimal therapeutic approaches.

• Learn to undertake a systematic evaluation of patients at risk for osteoporosis, including radiological examination and appropriate laboratory markers.

• Learn evidence-based approaches to reducing progression of osteoporosis, and reducing risk of fracture complications.

• Learn how to select safe and effective pharmacotherapy for prevention and treatment of postmenopausal osteoporosis.

• Learn how landmark trials and analyses focusing on BMD, bisphosphonate therapy, predictive risk, and fracture reduction should guide clinical management of patients with osteoporosis.

Disclaimer:

Copyright © 2011 Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2011 Resources, LLC All rights reserved.